Innovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes, weight loss study

27th October 2025 Uncategorised 0

Innovent’s Eli Lilly-partnered mazdutide, a GLP-1/glucagon (GCG) dual receptor agonist, displayed broader effects on patients’ blood glucose levels and weight loss than Novo’s leading GLP-1 semaglutide in a head-to-head trial.

More: Innovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes, weight loss study
Source: fierce